Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Robier, C; Amouzadeh-Ghadikolai, O; Bregant, C; Diez, J; Melinz, K; Quehenberger, F; Quasthoff, S.
The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
Int J Lab Hematol. 2017; 39(5):469-474
Doi: 10.1111/ijlh.12662
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Robier Christoph
- Co-authors Med Uni Graz
- Quasthoff Stefan
- Quehenberger Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aside from the extensive published data on immunophenotypic lymphocyte subsets in natalizumab-treated patients with multiple sclerosis (MS), an impact of natalizumab on lymphocyte morphology has rarely been studied. As patients treated with immunomodulating or immunosuppressive drugs are at risk for infectious disorders such as viral infections, knowledge of drug-derived changes in lymphocyte morphology may be beneficial in the diagnostic work-up in such clinical situations. This study aimed to determine the frequency of occurrence of atypical lymphocytes and defined subtypes of variant lymphocytes in natalizumab-treated patients with MS. We compared eight defined morphological lymphocyte subtypes in peripheral blood smears between 14 natalizumab-treated, 13 interferon-treated and 10 untreated subjects with relapse-remitting MS. Atypical lymphocytes were significantly enhanced in natalizumab-treated patients compared to the interferon and control group (P<.0001). Binucleated lymphocytes were restricted to the natalizumab group (P=.0058, P=.018), and plasmacytoid lymphocytes were more frequently found in the natalizumab group (P<.0001). Our data indicate that natalizumab enhances the fraction of atypical lymphocytes, and thereby especially the binucleated and plasmacytoid lymphocytes. Knowledge of these natalizumab-associated changes in lymphocyte morphology may be relevant in clinical routine, to avoid unnecessary diagnostic procedures or even a discontinuation of natalizumab treatment. © 2017 John Wiley & Sons Ltd.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Biopsy -
- Case-Control Studies -
- Female -
- Humans -
- Immunologic Factors - therapeutic use
- Interferons - therapeutic use
- Lymphocyte Count -
- Lymphocyte Subsets - metabolism
- Lymphocyte Subsets - pathology
- Lymphocytes - metabolism
- Lymphocytes - pathology
- Male -
- Middle Aged -
- Multiple Sclerosis - blood
- Multiple Sclerosis - drug therapy
- Multiple Sclerosis - pathology
- Natalizumab - therapeutic use
- Young Adult -
- Find related publications in this database (Keywords)
- atypical lymphocytes
- lymphocyte morphology
- lymphocytes
- multiple sclerosis
- natalizumab